KLRK1 and cancer: For example, while DNA-damaging agents, such as many chemotherapeutic drugs used to treat patients with different types of cancer, are able to elicit antitumor immune responses through the upregulation of immunostimulatory stress-regulating molecules such as NKG2D ligands, the same drugs also increase the expression of immunosuppressive axes, including certain inhibitory immune checkpoints, thereby facilitating cancer immune evasion (19).